Search

Showing total 1,906 results

Search Constraints

Start Over You searched for: Topic buprenorphine Remove constraint Topic: buprenorphine Language english Remove constraint Language: english
1,906 results

Search Results

51. Association between high-threshold practices and buprenorphine treatment termination.

52. Free Papers Compiled.

53. The methods and baseline characteristics of a multi-site randomized controlled trial evaluating mindfulness-based relapse prevention in conjunction with peer support to improve adherence to medications for opioid use disorders.

54. Exploring the effectiveness of a regional nurse practitioner led, long‐acting injectable buprenorphine‐based model of care for opioid use disorder.

55. Comparing the Antinociceptive Effects of Methamphetamine, Buprenorphine, or Both After Chronic Treatment and Withdrawal in Male Rats

56. Screening and Brief Intervention for Cannabis Misuse in Individuals on Buprenorphine Treatment for Opioid Use Disorder: Double-Blind Randomized Clinical Trial.

57. Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series.

58. Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.

59. Perinatal morphine but not buprenorphine affects gestational and offspring neurobehavioral outcomes in mice.

60. "Get in and get out, get on with life": Patient and provider perspectives on methadone van implementation for opioid use disorder treatment.

61. Application of an opioid use disorder cascade of care in a large public health system.

62. Monitoring medication and illicit drug consumption in a prison by wastewater-based epidemiology: Impact of COVID-19 restrictions.

63. A randomized, parallel group, pragmatic comparative-effectiveness trial comparing medication-assisted treatment induction methods in primary care practices: The HOMER study protocol.

64. Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders.

65. Trazodone for sleep disturbance in opioid dependent patients maintained on buprenorphine: A double blind, placebo-controlled trial.

66. Trajectories of drug treatment and illicit opioid use in the AIDS Linked to the IntraVenous Experience cohort, 2014-2019.

67. Beacon calls for primary care and MAT to expand opioid treatment access.

68. How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis.

69. Harmful effects of opioid use in pregnancy: A scientific review commissioned by the European Board and College of obstetrics and gynaecology (EBCOG).

70. Treatment of opioid use disorder in Ukraine during the first year of the Russia-Ukraine war: Lessons learned from the crisis.

71. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.

72. Patients' goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study.

73. Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids.

74. Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder.

75. Exploring potential moderators of depressive symptoms and treatment outcomes among patients with opioid use disorder.

76. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.

77. Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice

78. A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder.

79. Transdermal Patches Containing Opioids in the Treatment of Patients with Chronic Pain.

80. AATOD white paper on how OTPs can work with Bupe providers.

81. Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.

82. Health and correctional staff acceptability of depot buprenorphine in NSW prisons.

83. Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.

84. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder.

85. Rationale and design of a multisite randomized clinical trial examining an integrated behavioral treatment for veterans with co-occurring chronic pain and opioid use disorder: The pain and opioids integrated treatment in veterans (POSITIVE) trial.

86. Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review.

87. In-vitro and in-vivo evaluation of sustained-release buprenorphine using in-situ forming lipid-liquid crystal gels.

88. Erratum

89. Meeting demand for opioid dependency in an Inner London borough.

90. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder.

91. Factors to guide the use of extended-release buprenorphine formulations for specific patient populations.

92. Total cost of care associated with opioid use disorder treatment.

93. Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care.

94. Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.

95. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.

96. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.

97. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.

98. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts.

99. Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study.

100. Medication adherence research comes of age.